SSY Group(02005.HK): Two APIs Approved by NMPA for Marketing
NewTimeSpace News: SSY Group Limited (02005.HK) issued a voluntary announcement on February 27, 2026, stating that the Group’s metoclopramide and metoclopramide hydrochloride have been approved by the National Medical Products Administration (NMPA) for registration as APIs for use in marketed finished dosage forms.
These two APIs are dopamine D2 receptor antagonists and also act as 5-hydroxytryptamine 4 (5-HT4) receptor agonists, which promote gastrointestinal motility. They are primarily used for anti-emesis and the treatment of nausea, belching, abdominal distension, reflux esophagitis, and other related conditions.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Baloxavir Marboxil API Approved for Registration, Becoming the Third Domestic Enterprise with Such Approval
- SSY GROUP (02005.HK): Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection Obtain Drug Registration Approvals, Deemed to Have Passed Consistency Evaluation
- SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
- SSY Group (02005.HK): Trustee Acquires 1 Million Shares Under Restricted Share Incentive Scheme
- SSY GROUP(02005.HK): Trustee Purchases 2 Million Shares Under Restricted Share Award Scheme at Average Price of HK$2.1585
